Company Profiles

driven by the PitchBook Platform

Sopherion

Sopherion
2001 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Buyout/LBO LATEST DEAL TYPE
2 INVESTORS
Description

Developer of anti-cancer agents. The company anti-cancer agents uses Minicell Peptide Display screening technologies to identify therapies for cancer and related areas.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • PO Box 477
  • East Brunswick, NJ 08816
  • United States

+1 (203) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Sopherion’s full profile, request a free trial.

Sopherion Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Buyout/LBO 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 18-Feb-2009 0000 00000 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 23-Sep-2004 $47M $73M Completed Startup
1. Early Stage VC (Series A) 01-Mar-2003 $26M $26M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Sopherion Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Zoticon Bioventures Venture Capital Majority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0

Sopherion Executive Team (3)

Name Title Board
Seat
Contact
Info
Ronald Goldfarb Ph.D Co-Founder, Chief Education Officer, President, Chief Scientific Officer & Board Member

2 Former Executives

You’re viewing 1 of 3 executives. Get the full list »

Sopherion Board Members (2)

Name Representing Role Since Contact
Info
Asher Nathan Zoticon Bioventures Board Member 000 0000
Robert Harow Self Board Member 000 0000